Latest Insider Transactions at Phreesia, Inc. (PHR)
This section provides a real-time view of insider transactions for Phreesia, Inc. (PHR). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Phreesia, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Phreesia, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 19
2024
|
David Linetsky SVP, Life Sciences |
SELL
Open market or private sale
|
Indirect |
402
-5.34%
|
$9,246
$23.27 P/Share
|
|
Mar 18
2024
|
David Linetsky SVP, Life Sciences |
SELL
Open market or private sale
|
Indirect |
46
-0.61%
|
$1,012
$22.22 P/Share
|
|
Feb 09
2024
|
Janet Gunzburg Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
480
-1.21%
|
$13,440
$28.0 P/Share
|
|
Feb 02
2024
|
Janet Gunzburg Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
480
-1.2%
|
$12,960
$27.0 P/Share
|
|
Feb 01
2024
|
Janet Gunzburg Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
328
-0.81%
|
$8,200
$25.99 P/Share
|
|
Jan 31
2024
|
Gillian Munson Director |
BUY
Grant, award, or other acquisition
|
Direct |
392
+1.44%
|
$9,800
$25.48 P/Share
|
|
Jan 31
2024
|
Edward L Cahill Director |
BUY
Grant, award, or other acquisition
|
Direct |
392
+0.85%
|
$9,800
$25.48 P/Share
|
|
Jan 31
2024
|
Lainie Goldstein Director |
BUY
Grant, award, or other acquisition
|
Direct |
392
+1.24%
|
$9,800
$25.48 P/Share
|
|
Jan 17
2024
|
Chaim Indig Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
63,931
-4.99%
|
$1,534,344
$24.12 P/Share
|
|
Jan 17
2024
|
Evan Roberts Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
41,081
-5.16%
|
$985,944
$24.12 P/Share
|
|
Jan 17
2024
|
Allison C Hoffman General Counsel & Secretary |
SELL
Open market or private sale
|
Direct |
7,605
-5.26%
|
$182,520
$24.12 P/Share
|
|
Jan 17
2024
|
David Linetsky SVP, Life Sciences |
SELL
Open market or private sale
|
Direct |
30,659
-13.06%
|
$735,816
$24.12 P/Share
|
|
Jan 17
2024
|
Michael J. Davidoff SVP, Payer Business |
SELL
Open market or private sale
|
Direct |
17,677
-19.41%
|
$424,248
$24.12 P/Share
|
|
Jan 17
2024
|
Amy Beth Van Duyn SVP, Human Resources |
SELL
Open market or private sale
|
Direct |
10,213
-7.86%
|
$245,112
$24.12 P/Share
|
|
Jan 17
2024
|
Balaji Gandhi Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
9,192
-8.61%
|
$220,608
$24.12 P/Share
|
|
Jan 16
2024
|
Chaim Indig Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
3,586
-0.28%
|
$86,064
$24.55 P/Share
|
|
Jan 16
2024
|
Evan Roberts Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
2,247
-0.28%
|
$53,928
$24.55 P/Share
|
|
Jan 16
2024
|
Allison C Hoffman General Counsel & Secretary |
SELL
Open market or private sale
|
Direct |
1,316
-0.9%
|
$31,584
$24.55 P/Share
|
|
Jan 16
2024
|
David Linetsky SVP, Life Sciences |
SELL
Open market or private sale
|
Direct |
2,318
-0.98%
|
$55,632
$24.55 P/Share
|
|
Jan 16
2024
|
Michael J. Davidoff SVP, Payer Business |
SELL
Open market or private sale
|
Direct |
1,310
-1.42%
|
$31,440
$24.55 P/Share
|
|
Jan 16
2024
|
Amy Beth Van Duyn SVP, Human Resources |
SELL
Open market or private sale
|
Direct |
738
-0.56%
|
$17,712
$24.55 P/Share
|
|
Jan 16
2024
|
Balaji Gandhi Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
932
-0.87%
|
$22,368
$24.55 P/Share
|
|
Jan 12
2024
|
Janet Gunzburg Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
205
-0.51%
|
$4,920
$24.11 P/Share
|
|
Jan 02
2024
|
Chaim Indig Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
42,000
+3.17%
|
-
|
|
Jan 02
2024
|
Evan Roberts Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
22,000
+2.68%
|
-
|
|
Jan 02
2024
|
David Linetsky SVP, Life Sciences |
BUY
Grant, award, or other acquisition
|
Direct |
22,000
+8.49%
|
-
|
|
Jan 02
2024
|
Allison C Hoffman General Counsel & Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
30,500
+17.3%
|
-
|
|
Jan 02
2024
|
Amy Beth Van Duyn SVP, Human Resources |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+8.73%
|
-
|
|
Jan 02
2024
|
Balaji Gandhi Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
22,000
+16.97%
|
-
|
|
Dec 31
2023
|
Allison C Hoffman General Counsel & Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
255
+0.22%
|
$4,845
$19.68 P/Share
|
|
Dec 19
2023
|
Janet Gunzburg Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
118
-0.29%
|
$2,714
$23.72 P/Share
|
|
Dec 19
2023
|
David Linetsky SVP, Life Sciences |
SELL
Open market or private sale
|
Indirect |
25
-0.33%
|
$575
$23.72 P/Share
|
|
Dec 18
2023
|
David Linetsky SVP, Life Sciences |
SELL
Open market or private sale
|
Indirect |
234
-2.99%
|
$5,382
$23.15 P/Share
|
|
Nov 01
2023
|
Janet Gunzburg Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
298
-0.73%
|
$3,874
$13.38 P/Share
|
|
Oct 31
2023
|
Evan Roberts Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+3.72%
|
$60,000
$2.03 P/Share
|
|
Oct 31
2023
|
Edward L Cahill Director |
BUY
Grant, award, or other acquisition
|
Direct |
732
+1.59%
|
$9,516
$13.66 P/Share
|
|
Oct 31
2023
|
Lainie Goldstein Director |
BUY
Grant, award, or other acquisition
|
Direct |
732
+2.32%
|
$9,516
$13.66 P/Share
|
|
Oct 31
2023
|
Gillian Munson Director |
BUY
Grant, award, or other acquisition
|
Direct |
732
+2.7%
|
$9,516
$13.66 P/Share
|
|
Oct 16
2023
|
Balaji Gandhi Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
861
-1.0%
|
$13,776
$16.61 P/Share
|
|
Oct 16
2023
|
Michael J. Davidoff SVP, Payer Business |
SELL
Open market or private sale
|
Direct |
1,198
-1.28%
|
$19,168
$16.61 P/Share
|
|
Oct 16
2023
|
Allison C Hoffman General Counsel & Secretary |
SELL
Open market or private sale
|
Direct |
1,297
-1.12%
|
$20,752
$16.61 P/Share
|
|
Oct 16
2023
|
Amy Beth Van Duyn SVP, Human Resources |
SELL
Open market or private sale
|
Direct |
665
-0.56%
|
$10,640
$16.61 P/Share
|
|
Oct 16
2023
|
David Linetsky SVP, Life Sciences |
SELL
Open market or private sale
|
Direct |
2,078
-0.96%
|
$33,248
$16.61 P/Share
|
|
Oct 16
2023
|
Evan Roberts Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
1,971
-0.26%
|
$31,536
$16.61 P/Share
|
|
Oct 16
2023
|
Chaim Indig Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
3,295
-0.26%
|
$52,720
$16.61 P/Share
|
|
Sep 18
2023
|
Janet Gunzburg Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
125
-0.3%
|
$2,375
$19.79 P/Share
|
|
Sep 18
2023
|
David Linetsky SVP, Life Sciences |
SELL
Open market or private sale
|
Indirect |
130
-0.55%
|
$2,470
$19.7 P/Share
|
|
Sep 14
2023
|
Amy Beth Van Duyn SVP, Human Resources |
SELL
Open market or private sale
|
Direct |
2,000
-1.66%
|
$40,000
$20.16 P/Share
|
|
Sep 14
2023
|
Allison C Hoffman General Counsel & Secretary |
SELL
Open market or private sale
|
Direct |
2,210
-1.86%
|
$44,200
$20.17 P/Share
|
|
Sep 14
2023
|
Michael J. Davidoff SVP, Payer Business |
SELL
Open market or private sale
|
Direct |
2,953
-3.06%
|
$59,060
$20.16 P/Share
|